Sildenafil oral spray achieves faster absorption vs sildenafil tablets Sildenafil > oral sildenafil Route of administration What special precautions should I follow? Renal Dose Adjustments Dose Adjustments Side Effects Publication types MeSH terms Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels phenobarbital Route of administration ketoconazoleketoconazole will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with strong CYP3A4 inhibitors and sildenafil (for pulmonary arterial hypertension) is not recommended. When used for erectile dysfunction, consider reducing initial sildenafil dose of 25 mg in patients also taking a strong CYP3A4 inhibitor and monitor for sildenafil toxicities (eg, dyspepsia, headache, hypotension). ketoconazole will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lenacapavirlenacapavir will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review Refer to the prescribing information of PDE5 inhibitors for dose recommendations. lenacapavir will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. levoketoconazole will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lonafarniblonafarnib will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling. will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Product Dosage Quantity + Bonus Price Viagra Generic200mg90 + 6 Pills170.79€ 162.66€Buy Kamagra100mg12 Pills55.64€ 52.99€Buy Viagra Generic25mg30 + 4 Pills47.97€ 45.69€Buy Viagra Generic100mg10 Pills28.91€ 27.53€Buy Viagra Generic50mg10 Pills26.87€ 25.59€Buy Kamagra Oral Jelly100mg30 + 5 Sachets136.20€ 129.71€Buy Kamagra100mg32 Pills121.24€ 115.47€Buy Viagra Generic50mg120 + 6 Pills129.64€ 123.47€Buy Kamagra Soft Tabs100mg272 + 12 Pills593.42€ 565.16€Buy Viagra Generic150mg90 + 6 Pills147.18€ 140.17€Buy Kamagra100mg84 + 6 Pills264.44€ 251.85€Buy Viagra Generic150mg180 + 10 Pills236.46€ 225.20€Buy Kamagra Soft Tabs100mg120 + 6 Pills311.78€ 296.93€Buy Viagra Generic150mg20 Pills55.02€ 52.40€Buy Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels phenoxybenzaminesildenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. Sildenafil is used to treat erectile dysfunction and pulmonary hypertension.It belongs to the class of phosphodiesterase inhibitors.Oral sildenafil should be taken about 30-60 minutes before activity. sildenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. Condition Caution / Notes Risk Factors Cardiovascular disease Use with caution Heart failure, recent MI Concomitant nitrate use Absolute contraindication Risk of severe hypotension Severe hepatic impairment May require dose adjustment Reduced clearance Retinitis Pigmentosa Cautious use Potential for vision disturbances phentolaminesildenafil increases effects of phentolamine by pharmacodynamic synergism. What special precautions should I follow? Patients receiving indinavir with ritonavir should receive not more than 25 mg of sildenafil for treatment of erectile dysfunction in lovegra sildenafil a 48-hour period, and patients receiving other protease inhibitors should use a lower initial sildenafil dose of 25 mg. Patient taking sildenafil for PAH with ritonavir is not recommended. pentobarbitalpentobarbital will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels pentobarbital will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels phenobarbitalphenobarbital will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sildenafil increases effects of phentolamine by pharmacodynamic synergism. Renal Dose Adjustments clarithromycin will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. conivaptanconivaptan will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Delay initiation of treatment with any CYP3A4 substrates for at least 7 days following discontinuation of conivaptan. conivaptan will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. crizotinibcrizotinib increases levels of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Marketing and sales If concomitant use of strong CYP3A inhibitors is unavoidable, reduce crizotnib to 250 mg PO qDay. After discontinuation of a strong CYP3A inhibitor, pfizer sildenafil 100 resume crizotinib dose used prior to initiating the strong CYP3A4 inhibitor. crizotinib increases levels of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dabrafenibdabrafenib will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels dabrafenib will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dose (mg) Typical Usage Frequency Time to Onset (minutes) Duration of Effect (hours) Notes 50 Once or twice daily 30-60 4-6 Starting dose for most patients 100 Once daily 30-60 4-6 Common for moderate ED 25 As needed 30-60 4-6 For mild ED 10 As needed 30-60 4-6 Lower dose option Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels phenytoin Dose Adjustments Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels doxazosinsildenafil increases effects of doxazosin by pharmacodynamic synergism. sildenafil increases effects of doxazosin by pharmacodynamic synergism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels eslicarbazepine acetate will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels fexinidazolefexinidazole will increase the level or effect 50 mg sildenafil price of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration may increase risk for adverse effects of CYP3A4 substrates. Altitude sickness fexinidazole will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ivosidenibivosidenib will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. ivosidenib will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Side Effects lonafarnib will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lopinavirlopinavir will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lopinavir will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristonemifepristone will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristone will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. How were the studies combined? mitotanemitotane decreases levels of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels. mitotane decreases levels of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nafcillinnafcillin will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels nafcillin will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels prazosinsildenafil increases effects of prazosin by pharmacodynamic synergism. Sildenafil is not a cure for erectile dysfunction but helps improve function.Use sildenafil only as prescribed to ensure safety and efficacy.It is not intended for recreational use and can be harmful. sildenafil increases effects of prazosin by pharmacodynamic synergism. Publication types Coadministration of PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, vardenafil) and guanylate cyclase stimulators (eg, riociguat) is contraindicated due to risk of additive hypotension; do not administer within 24 hr of each other. Either increases effects of the other by pharmacodynamic synergism. Coadministration of vericiguat with PDE-5 inhibitors may result in additive hypotensive effects. alfuzosinsildenafil increases effects of alfuzosin by pharmacodynamic synergism. sildenafil increases effects of alfuzosin by pharmacodynamic synergism. Journal of Urology apalutamideapalutamide will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed. primidoneprimidone will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Parameter Description Typical Value Notes Absorption Rate How quickly sildenafil enters bloodstream Rapid Peaks in 30-120 minutes Bioavailability Percentage of dose reaching systemic circulation ~40% Affected by food intake Half-life Time for plasma concentration to reduce by half 3-5 hours Determines dosing frequency Peak Plasma Concentration Maximum concentration after dose 1 hour Influenced by gastric emptying and food intake Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels primidone MeSH terms apalutamide will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. asenapinesildenafil increases effects of asenapine by pharmacodynamic synergism. sildenafil increases effects of asenapine by pharmacodynamic synergism. ceritinibceritinib will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinib will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Before taking sildenafil, chloramphenicolchloramphenicol will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. chloramphenicol will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. clarithromycinclarithromycin will increase the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of these phosphodiesterase inhibitors with clarithromycin, a CYP3A4 inhibitor is not recommended. Increased systemic exposure of these drugs may occur with clarithromycin; consider reduction of dosage for phosphodiesterase inhibitors. will decrease the level or effect of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels relacorilantrelacorilant increases levels of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Always consult a healthcare provider before starting sildenafil.Do not exceed the prescribed dose to avoid side effects.Sildenafil can interact with nitrates, causing dangerous blood pressure drops. Safety and Tolerability Profile of Sildenafil for Ejaculation Disorders 16 HOW SUPPLIED/STORAGE AND HANDLING Terms and conditions Cialis 20 mg Tadalafil Tablets for Erectile Dysfunction 30 Tablets Managing Expectations for Libido Medications Αγορα Viagra Απο Φαρμακειο Sildénafil : comment utiliser le médicament générique du viagra ?